Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies

Daisuke Ikeda; Toshiki Terao; Ami Fukumoto; Yuka Uesugi; Rikako Tabata; Ayumi Kuzume; Takafumi Tsushima; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Takeshi Yamashita; Hiroyuki Takamatsu; Kosei Matsue

doi:10.1111/bjh.18549

Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies

Daisuke Ikeda, Toshiki Terao, Ami Fukumoto, Yuka Uesugi, Rikako Tabata, Ayumi Kuzume, Takafumi Tsushima, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Takeshi Yamashita, Hiroyuki Takamatsu, Kosei Matsue

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Antibody titres in 462 patients with haematological malignancies after the second (D2) and third (D3) SARS-CoV-2 vaccine were compared with those of healthy controls (HCs). Significant decay of antibody titre was observed pre D3, but titre surged post D3. The number of seronegative patients decreased from 79 (17.1%) to 44 (9.5%) from post D2 to post D3, and patients with adequate antibody titre increased from 204 (44.2%) to 358 (77.5%). Of the patients who received B-cell-targeted therapy, 80% were seronegative and 71% remained seronegative after D3. CD19+, CD4+, CD8+ cell counts, and immunoglobulin G (IgG) levels were identified as independent predictors for adequate serologic response.

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.18549
Publication status	Accepted/In press - 2022
Externally published	Yes

Keywords

anti-CD20 monoclonal antibody
booster vaccination
BTK inhibitor
haematologic malignancies
SARS-CoV-2

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.18549

Cite this

@article{e63e14008f6747429234ac9947e657b6,

title = "Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies",

abstract = "Antibody titres in 462 patients with haematological malignancies after the second (D2) and third (D3) SARS-CoV-2 vaccine were compared with those of healthy controls (HCs). Significant decay of antibody titre was observed pre D3, but titre surged post D3. The number of seronegative patients decreased from 79 (17.1%) to 44 (9.5%) from post D2 to post D3, and patients with adequate antibody titre increased from 204 (44.2%) to 358 (77.5%). Of the patients who received B-cell-targeted therapy, 80% were seronegative and 71% remained seronegative after D3. CD19+, CD4+, CD8+ cell counts, and immunoglobulin G (IgG) levels were identified as independent predictors for adequate serologic response.",

keywords = "anti-CD20 monoclonal antibody, booster vaccination, BTK inhibitor, haematologic malignancies, SARS-CoV-2",

author = "Daisuke Ikeda and Toshiki Terao and Ami Fukumoto and Yuka Uesugi and Rikako Tabata and Ayumi Kuzume and Takafumi Tsushima and Daisuke Miura and Kentaro Narita and Masami Takeuchi and Takeshi Yamashita and Hiroyuki Takamatsu and Kosei Matsue",

note = "Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

doi = "10.1111/bjh.18549",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies

AU - Ikeda, Daisuke

AU - Terao, Toshiki

AU - Fukumoto, Ami

AU - Uesugi, Yuka

AU - Tabata, Rikako

AU - Kuzume, Ayumi

AU - Tsushima, Takafumi

AU - Miura, Daisuke

AU - Narita, Kentaro

AU - Takeuchi, Masami

AU - Yamashita, Takeshi

AU - Takamatsu, Hiroyuki

AU - Matsue, Kosei

PY - 2022

Y1 - 2022

N2 - Antibody titres in 462 patients with haematological malignancies after the second (D2) and third (D3) SARS-CoV-2 vaccine were compared with those of healthy controls (HCs). Significant decay of antibody titre was observed pre D3, but titre surged post D3. The number of seronegative patients decreased from 79 (17.1%) to 44 (9.5%) from post D2 to post D3, and patients with adequate antibody titre increased from 204 (44.2%) to 358 (77.5%). Of the patients who received B-cell-targeted therapy, 80% were seronegative and 71% remained seronegative after D3. CD19+, CD4+, CD8+ cell counts, and immunoglobulin G (IgG) levels were identified as independent predictors for adequate serologic response.

AB - Antibody titres in 462 patients with haematological malignancies after the second (D2) and third (D3) SARS-CoV-2 vaccine were compared with those of healthy controls (HCs). Significant decay of antibody titre was observed pre D3, but titre surged post D3. The number of seronegative patients decreased from 79 (17.1%) to 44 (9.5%) from post D2 to post D3, and patients with adequate antibody titre increased from 204 (44.2%) to 358 (77.5%). Of the patients who received B-cell-targeted therapy, 80% were seronegative and 71% remained seronegative after D3. CD19+, CD4+, CD8+ cell counts, and immunoglobulin G (IgG) levels were identified as independent predictors for adequate serologic response.

KW - anti-CD20 monoclonal antibody

KW - booster vaccination

KW - BTK inhibitor

KW - haematologic malignancies

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85141486593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141486593&partnerID=8YFLogxK

U2 - 10.1111/bjh.18549

DO - 10.1111/bjh.18549

M3 - Article

AN - SCOPUS:85141486593

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this